DINAQUBE
LIVE

Serial Number

79373372

Owner

DiNAQOR AG

Attorney

Alexander P. Montgomery

Filing Date

Feb 14, 2023

Add to watchlist:

No watchlists yet
View on USPTO

DINAQUBE Trademark

Serial Number: 79373372 • Registration: 7602045

DINAQUBE is a trademark filed by DiNAQOR AG on February 14, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

DiNAQOR AG (4 trademarks)

Wagistrasse 25

Entity Type: 25

Trademark Details

Filing Date

February 14, 2023

Registration Date

December 17, 2024

Published for Opposition

October 29, 2024

Goods & Services

surgical implants comprising artificial material, namely, artificial heart tissue

Active chemical ingredients for use in the manufacture of medicines for heart disease

recorded and downloadable computer software and computer software platforms for the development of gene therapies; recorded and downloadable computer software and computer software platforms for use in medical, biomedical, veterinary and pharmaceutical research and development; scientific, research, navigation, surveying, photographic, cinematographic, audiovisual, optical, measuring, signaling, detection, testing, inspection, and teaching apparatus and instruments in the nature of high speed cameras, electric sensors and electric actuators, optical 2D scanners, optical filters, and photomultiplier tubes for use in medical, biomedical, veterinary and pharmaceutical research and development; weighing apparatus and instruments for use in medical, biomedical, veterinary and pharmaceutical research and development; data processing and computer equipment in the nature of video-optical recording devices for use in medical, biomedical, veterinary and pharmaceutical research and development

development and programming of software and computer platforms for use in medical, biomedical, veterinary and pharmaceutical research and development; Platform as a service (PAAS) featuring computer software platforms for use in medical, biomedical, veterinary and pharmaceutical research and development; stem cell research services; consulting services relating to medical, biomedical, veterinary and pharmaceutical research and development; research relating to medical, biomedical, veterinary and pharmaceutical research and development; obtaining and providing information and data relating to medical, biomedical, veterinary and pharmaceutical research and development; Biological research and analysis, namely, analysis of human tissue for medical, biomedical, veterinary and pharmaceutical research purposes; design and development of medical diagnostic apparatus; scientific research and development with respect to the isolation and cultivation of human cells and tissues; Programming of computer software for others, namely, programming of software for information platforms on the Internet for use in medical, biomedical, veterinary and pharmaceutical research and development; Rental of laboratory apparatus and instruments for scientific, research, navigation, surveying, photographic, cinematographic, audiovisual, optical, weighing, measuring, signaling, detection, testing, inspection and teaching purposes for use in medical, biomedical, veterinary and pharmaceutical research and development; rental and provision for other purposes of computer hardware and data processing equipment for use in medical, biomedical, veterinary and pharmaceutical research and development

providing medical information in the field of medical care as it relates to the preparation and dispensing of medications, in particular for cardiomyopathies and heart failure; Providing medical information and consulting services in the field of medical care as it relates to medical, biomedical, veterinary and pharmaceutical products; genetic screening for medical, biomedical, veterinary and pharmaceutical purposes; human heart tissue bank services; medical services relating to the removal, treatment and processing of stem cells

pharmaceutical preparations and substances, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals in the nature of viral vectors; Medicinal and biomedical preparations and substances, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals in the nature of viral vectors; biological solid organ tissue intended for subsequent implantation; surgical implants made of living tissue; biochemical preparations for the treatment of genetic diseases and cancers; stem cells for medical use; pharmaceutical, medical, biomedical and veterinary preparations, in particular for the treatment of heart diseases

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 17, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 17, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 29, 2024 NPUB
PUBLISHED FOR OPPOSITION
Oct 29, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 9, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 20, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 20, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 20, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 20, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 20, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 19, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 19, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Sep 19, 2024 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jul 12, 2024 GNFN
FINAL REFUSAL E-MAILED
Jul 12, 2024 GNFR
FINAL REFUSAL WRITTEN
Jul 12, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
May 21, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 21, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 21, 2024 TROA
REFUSAL PROCESSED BY IB
Dec 19, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 30, 2023 RFCS
REFUSAL PROCESSED BY MPU
Nov 30, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Nov 29, 2023 RFCR
NON-FINAL ACTION WRITTEN
Nov 28, 2023 CNRT
ASSIGNED TO EXAMINER
Nov 14, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 11, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 7, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 6, 2023 REPR